SCHEDULE: Sofinnova Group Ownership Below 5% in Jade Biosciences
Beneficial Ownership Update
Sofinnova Venture Partners X and its affiliates now hold less than 5% of Jade Biosciences' common stock following a merger and reverse stock split.
Summary
- This Amendment No. 3 to Schedule 13D updates the beneficial ownership of Common Stock in Jade Biosciences, Inc. (formerly Aerovate Therapeutics, Inc.) by Sofinnova Venture Partners X, L.P. and its affiliated reporting persons.
- The reporting persons collectively beneficially own 107,391 shares, which represents 0.3% of the Issuer's outstanding Common Stock.
- This change in ownership percentage is a direct result of the merger between Jade Biosciences, Inc. and Aerovate Therapeutics, Inc. on April 28, 2025, and a preceding 1-for-35 reverse stock split.
- As a consequence of these corporate actions, the reporting persons ceased to own more than five percent (5%) of the Issuer's outstanding Common Stock as of April 28, 2025.
- Dr. Maha Katabi, a managing member of Sofinnova Management X-A, L.L.C., resigned as a member of the board of directors of the Issuer on October 6, 2024.
- The reporting persons hold their securities for investment purposes and may adjust their holdings based on various market and company-specific factors.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral. It primarily serves as a factual update on beneficial ownership following corporate restructuring (merger and reverse split) and does not contain new information regarding the company's operational performance or strategic direction.
Positives
- The reporting persons maintain an investment in Jade Biosciences, indicating continued, albeit reduced, interest in the company's future.
Negatives
- The reduction in beneficial ownership below the 5% threshold by a significant institutional investor group could be perceived by some investors as a decrease in conviction or a strategic reduction in exposure.
Future Outlook
The reporting persons hold their securities for investment purposes and may, from time to time, acquire additional common stock, retain, sell, or distribute their holdings. Future actions will depend on factors such as stock price levels, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations, prospects, and alternative investment opportunities.
Industry Context
StockSavvy.ai notes that Schedule 13D amendments like this are routine disclosures following significant corporate actions such as mergers and reverse stock splits. While the reduction in beneficial ownership below 5% by a venture capital group like Sofinnova could sometimes signal a shift in investment strategy, in this context, it appears to be a mechanical adjustment due to the dilution effect of the merger and the reverse stock split rather than an active divestment decision.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Dr. Maha Katabi | N/A | October 6, 2024 | Resignation from the board of directors of the Issuer. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Existing Agreement Reference | SVP X is a party to an Investors' Rights Agreement among the Issuer, SVP X, and other shareholders, which grants certain registration rights. | August 5, 2020 | Provides SVP X with the ability to demand or request inclusion in registration statements, potentially enhancing liquidity for its holdings. |
| Existing Agreement Reference | Dr. Maha Katabi, in her capacity as a director, entered into an Indemnification Agreement with the Issuer. | N/A (referenced as existing) | Offers protection to Dr. Katabi against certain liabilities arising from her service as a director. |
| Existing Agreement Reference | SVP X and Dr. Maha Katabi were subject to a Lock-Up Agreement for 180 days after the Prospectus date, restricting the sale of Common Stock. | N/A (referenced as existing, likely expired) | Temporarily restricted the ability of these reporting persons to sell shares, which is a common practice to stabilize the stock price post-IPO. |
Legal Proceedings
- None of the Reporting Persons have been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) in the last five years.
- None of the Reporting Persons have been a party to a civil proceeding resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws in the last five years.
Related Party Transactions
- Dr. Maha Katabi, a managing member of Sofinnova Management X-A, L.L.C. and former director of the Issuer, received multiple stock option grants from the Issuer between June 2021 and June 2024, some of which were awarded in lieu of cash compensation.
Stakeholder Impact
- Shareholders: The reduction in beneficial ownership by a significant institutional investor group like Sofinnova, while a technical adjustment, might be viewed by some shareholders as a decrease in institutional support, though the filing indicates an ongoing investment purpose. The merger and reverse stock split themselves have a more direct impact on share structure and value.
- Management: Dr. Katabi's resignation from the board of directors on October 6, 2024, indicates a change in the composition of the Issuer's governance.
Next Steps
- Reporting persons may acquire additional Common Stock.
- Reporting persons may retain or sell all or a portion of their Common Stock.
- Reporting persons may distribute Common Stock to their respective members or limited partners.
Key Dates
| Date | Description |
|---|---|
| August 5, 2020 | Sofinnova Venture Partners X, L.P. (SVP X) purchased Series A redeemable convertible preferred stock and became a party to an Investors' Rights Agreement. |
| February 1, 2021 | SVP X purchased additional Series A redeemable convertible preferred stock. |
| June 4, 2021 | SVP X purchased additional Series A redeemable convertible preferred stock. |
| June 29, 2021 | Dr. Maha Katabi was granted a stock option to purchase 25,000 shares of Common Stock at an exercise price of $14.00 per share. |
| June 30, 2021 | The Issuer's Prospectus was filed, detailing SVP X's purchase of 357,142 shares of Common Stock at $14.00 per share in connection with the Offering. |
| July 1, 2021 | Dr. Maha Katabi was granted a stock option to purchase 2,467 shares of Common Stock at an exercise price of $19.41 per share, awarded in lieu of cash compensation. |
| July 13, 2021 | The initial Statement on Schedule 13D was filed. |
| January 3, 2022 | Dr. Maha Katabi was granted a stock option to purchase 7,240 shares of Common Stock at an exercise price of $10.93 per share, awarded in lieu of cash compensation. |
| June 21, 2022 | Dr. Maha Katabi was granted a stock option to purchase 12,500 shares of Common Stock at an exercise price of $12.26 per share. |
| January 3, 2023 | Dr. Maha Katabi was granted a stock option to purchase 2,627 shares of Common Stock at an exercise price of $27.03 per share, awarded in lieu of cash compensation. |
| February 3, 2023 | The Agreement of Joint Filing for the Schedule 13D was signed. |
| February 6, 2023 | The Statement on Schedule 13D was amended. |
| June 6, 2023 | Dr. Maha Katabi was granted a stock option to purchase 12,500 shares of Common Stock at an exercise price of $16.30 per share. |
| January 2, 2024 | Dr. Maha Katabi was granted a stock option to purchase 3,519 shares of Common Stock at an exercise price of $21.81 per share, awarded in lieu of cash compensation. |
| February 20, 2024 | The Statement on Schedule 13D was amended. |
| June 5, 2024 | Dr. Maha Katabi was granted a stock option to purchase 12,500 shares of Common Stock at an exercise price of $18.90 per share. |
| October 6, 2024 | Dr. Maha Katabi resigned as a member of the board of directors of the Issuer. |
| October 30, 2024 | The Agreement and Plan of Merger between Jade Biosciences, Inc. and Aerovate Therapeutics, Inc. was dated. |
| April 28, 2025 | The merger of Jade Biosciences, Inc. and Aerovate Therapeutics, Inc. closed, and a 1-for-35 reverse stock split was effected. The Reporting Persons ceased to own more than 5% of the Issuer's Common Stock. |
| September 30, 2025 | Date as of which 32,626,730 shares of Common Stock were outstanding, used for calculating beneficial ownership percentage. |
| December 30, 2025 | The Issuer's Form 424(b)(3) was filed, reporting the number of outstanding shares of Common Stock. |
| March 5, 2026 | Date of signing for this Amendment No. 3 to Schedule 13D. |
Recommendation
holdThis Schedule 13D amendment primarily reports a technical adjustment in beneficial ownership following a merger and reverse stock split, rather than a new strategic investment or divestment decision. The reporting persons' stake falling below 5% is a consequence of these corporate actions. Without further information on the company's operational performance or future strategy, the filing itself does not provide a strong basis for a 'buy' or 'sell' recommendation. A 'hold' recommendation is appropriate as investors should await more comprehensive financial and operational updates from Jade Biosciences, Inc. to assess its prospects post-merger.
Keywords
Jade Biosciences, Aerovate Therapeutics, Sofinnova Venture Partners, Schedule 13D, Beneficial Ownership, Reverse Stock Split, Merger, Common Stock, Investment, Venture Capital
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.